SAB Biotherapeutics, Inc. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

SAB Biotherapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $0.00 for the year ending 2025.

  • SAB Biotherapeutics, Inc. showed a decrease of -100.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from SAB Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), SAB Biotherapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 100.0%.
  • Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $1.32 million | Fiscal year 2023: $2.24 million | Fiscal year 2022: $23.90 million | Fiscal year 2021: $60.88 million | Fiscal year 2020: $55.24 million.
  • Data sourced from SEC EDGAR public filings as of June 24, 2026.

Last verified: